Browsing Over 107 Presentations
Welcome to the ESMO Gynaecological Cancers Congress 2022
- The Panelists (Valencia, Spain)
Recent developments in adjuvant treatment
- Carien L. Creutzberg (Leiden, Netherlands)
New treatment options for advanced and metastatic disease
- Alexandra Leary (Villejuif, France)
Live Q&A
- Carien L. Creutzberg (Leiden, Netherlands)
Introduction
- Mansoor Raza Mirza (Copenhagen, Denmark)
Recent developments in surgery for early-stage disease
- Christian Marth (Innsbruck, Austria)
Should we really use PD-L1 as a selection driver in cervical cancer?
- Bradley J. Monk (Phoenix, AZ, United States of America)
MMR status, TMB or both: How to identify endometrial cancer patients who benefit the most from immunotherapy
- Vicky Makker (New York City, NY, United States of America)
Digging into molecular characterization of high-grade ovarian cancer: BRCA, HRD and beyond
- Nicole Concin (Innsbruck, Austria)
The role of MAPK pathway to select therapy in low-grade ovarian cancer
- Susana Banerjee (London, United Kingdom)
Live Q&A
- Bradley J. Monk (Phoenix, AZ, United States of America)
11P - Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer
- Tullio Golia D'Auge (Rome, Italy)
Abstract
Background
To evaluate the impact of the Laparoscopic Approach to Cervical Cancer (LACC) trial on patterns of care and surgery-related morbidity in early-stage cervical cancer.
Methods
This is a retrospective, multi-institutional study evaluating 90-day surgery-related outcomes of patients undergoing treatment for early-stage cervical cancer before (period I: 01/01/2016-06/01/2018) and after (period II: 01/01/2019-06/01/2021) the publication of the results of the LACC trial.
Results
Charts of 1,295 patients were evaluated: 581 (44.9%) and 714 (55.1%) before and after the publication of the LACC trial, respectively. After the publication of the LACC trial the number of patients treated with minimally-invasive radical hysterectomy decreased from 64.9% to 30.4% (p<0.001). Overall, 90-day complications occurred in 110 (18.9%) and 119 (16.6%) patients in the period I and period II, respectively (p=0.795). Similarly, the number of severe (grade 3 or worse) complications did not differ between the two periods (38 (6.5%) vs. 37 (5.1%); p=0.297). Overall and severe 90-day complications were consistent between periods even evaluating stage IA (p=0.471), IB1 (p=0.929), and IB2 (p=0.074), separately.
Conclusions
The present investigation highlighted that in referral centers the shift from minimally invasive to open radical hysterectomy does not influence 90-day surgery-related morbidity.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.